Ce fi derocol Is an Effective Topical Monotherapy for Experimental Extensively Drug-Resistant Pseudomonas aeruginosa Keratitis

被引:3
作者
Romanowski, Eric G. [1 ]
Mumper, Sonya M. [1 ]
Shanks, Hazel Q. [1 ]
Yates, Kathleen A. [1 ]
Mandell, Jonathan B. [1 ]
Zegans, Michael E. [2 ,3 ]
Shanks, Robert M. Q. [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Charles T Campbell Lab Ophthalm Microbiol, Pittsburgh, PA 15219 USA
[2] Geisel Sch Med Dartmouth, Dept Surg, Hanover, NH USA
[3] Geisel Sch Med Dartmouth, Dept Microbiol & Immunol, Hanover, NH USA
来源
OPHTHALMOLOGY SCIENCE | 2024年 / 4卷 / 04期
基金
美国国家卫生研究院;
关键词
Antibiotic resistance; Ce fi derocol; Keratitis; Ocular infection; Pseudomonas aeruginosa; IN-VITRO; GATIFLOXACIN; 0.3-PERCENT; BACTERIAL KERATITIS; MICROBIAL KERATITIS; RISK-FACTORS; CIPROFLOXACIN; CEFIDEROCOL;
D O I
10.1016/j.xops.2023.100452
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To test cefiderocol, a siderophore-cephalosporin antibiotic for topical monotherapy treatment of experimental extensively drug -resistant (XDR) Pseudomonas aeruginosa keratitis. Design: Preclinical study. Subjects and Controls: Deidentified P. aeruginosa keratitis isolates, XDR P. aeruginosa from eye drop outbreak, rabbits, saline, cefiderocol 50 mg/ml, ciprofloxacin 0.3%, and tobramycin 14 mg/ml. Methods, Intervention, or Testing: Cefiderocol antibacterial activity against P. aeruginosa keratitis isolates (n = 135) was evaluated by minimum inhibitory concentration (MIC) testing. Ocular toxicity/tolerability and antibacterial efficacy were tested in vivo with experimental rabbit models. Corneal concentrations and stability were assessed using a bioassay. Main Outcome Measures: Minimum inhibitory concentration analysis for susceptibility, graded tests for ocular toxicity/tolerability, colony -forming unit (CFU) analysis for bacterial burden, corneal cefiderocol concentrations. Results: One hundred percent of P. aeruginosa keratitis isolates were susceptible to cefiderocol (n = 135), the MIC 90 was 0.125 mg/ml including the XDR isolate (MIC = 0.125 mg/ml). Topical cefiderocol 50 mg/ml was minimally toxic to the ocular surface and was well tolerated. For the XDR P. aeruginosa isolate, topical cefiderocol 50 mg/ml, significantly decreased corneal CFU compared with ciprofloxacin 0.3%, tobramycin 14 mg/ml, and saline. In addition, tobramycin 14 mg/ml was more effective than the saline control. Mean cefiderocol corneal concentrations were 191x greater than the MIC 90 of the P. aeruginosa keratitis isolates. Refrigerated cefiderocol maintained antimicrobial activity over a 1 -month period. Conclusions: These results demonstrate that cefiderocol is well tolerated on rabbit corneas and is effective against P. aeruginosa keratitis isolates in vitro and was effective in vivo against an XDR isolate in a rabbit keratitis model. Given the recent outbreak of keratitis caused by this XDR P. aeruginosa , cefiderocol is a promising additional antibiotic that should be further evaluated for topical treatment of keratitis caused by antibiotic resistant P. aeruginosa . Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. Ophthalmology Science 2024;4:100452 (c) 2023 by the American Academy of Ophthalmology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页数:10
相关论文
共 46 条
[21]  
Kowalski RP, 2018, J. Clin. Ophthalmol. Optom, V2, P103
[22]   The fixed combination of fortified vancomycin and amikacin ophthalmic solution-VA solution - In vitro study of the potency and stability [J].
Lin, JM ;
Tsai, YY ;
Fu, YL .
CORNEA, 2005, 24 (06) :717-721
[23]   Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: A network meta-analysis of randomised clinical trials [J].
Lin, Meng-Hsuan ;
Shen, Yi-Cheng ;
Cheng, Han-Yun ;
Teng, Chi-Kang ;
Chen, Wei-Cheng ;
Lin, Yu-Chao ;
Hung, Chin-Chuan .
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2023, 34 :46-58
[24]   Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance [J].
Magiorakos, A. -P. ;
Srinivasan, A. ;
Carey, R. B. ;
Carmeli, Y. ;
Falagas, M. E. ;
Giske, C. G. ;
Harbarth, S. ;
Hindler, J. F. ;
Kahlmeter, G. ;
Olsson-Liljequist, B. ;
Paterson, D. L. ;
Rice, L. B. ;
Stelling, J. ;
Struelens, M. J. ;
Vatopoulos, A. ;
Weber, J. T. ;
Monnet, D. L. .
CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (03) :268-281
[25]   Zymar (Gatifloxacin 0.3%) shows excellent gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand white rabbit keratitis model [J].
Mah, Francis S. ;
Romanowski, Eric G. ;
Kowalski, Regis P. ;
Yates, Kathleen A. ;
Gordon, Y. Jerold .
CORNEA, 2007, 26 (05) :585-588
[26]   In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa [J].
Malisova, Lucia ;
Vrbova, Iveta ;
Pomorska, Katarina ;
Jakubu, Vladislav ;
Zemlickova, Helena .
MICROBIAL DRUG RESISTANCE, 2023, 29 (10) :485-491
[27]   Use of topical colistin in bacterial keratitis caused by extensively drug-resistant Pseudomonas Aeruginosa: a case report [J].
Maticorena-Quevedo, Jesus ;
Patino-Valderrama, Lia ;
Arellano-Caro, Karin .
ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2023, 86 (04) :384-387
[28]   Clinical and microbiological profile of infectious keratitis in an area of Madrid, Spain [J].
Mediero, Soraya ;
Boto de los Bueis, Ana ;
Spiess, Karina ;
Diaz-Almiron, Mariana ;
del Hierro Zarzuelo, Almudena ;
Villalain Rodes, Isabel ;
Garcia Perea, Adela .
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2018, 36 (07) :409-416
[29]   Investigating and Treating a Corneal Ulcer Due to Extensively Drug-Resistant Pseudomonas aeruginosa [J].
Morelli, Morgan K. ;
Kloosterboer, Amy ;
Fulton, Scott A. ;
Furin, Jennifer ;
Newman, Nicholas ;
Omar, Ahmed F. ;
Rojas, Laura J. ;
Marshall, Steven H. ;
Yasmin, Mohamad ;
Bonomo, Robert A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (07)
[30]   US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®) [J].
Naseer, Shabnam ;
Weinstein, Edward A. ;
Rubin, Daniel B. ;
Suvarna, Kalavati ;
Wei, Xiaohui ;
Higgins, Karen ;
Goodwin, Avery ;
Jang, Seong H. ;
Iarikov, Dmitri ;
Farley, John ;
Nambiar, Sumathi .
CLINICAL INFECTIOUS DISEASES, 2021, 72 (12) :E1103-E1111